Emmenegger Marc, De Cecco Elena, Lamparter David, Jacquat Raphaël P B, Riou Julien, Menges Dominik, Ballouz Tala, Ebner Daniel, Schneider Matthias M, Morales Itzel Condado, Doğançay Berre, Guo Jingjing, Wiedmer Anne, Domange Julie, Imeri Marigona, Moos Rita, Zografou Chryssa, Batkitar Leyla, Madrigal Lidia, Schneider Dezirae, Trevisan Chiara, Gonzalez-Guerra Andres, Carrella Alessandra, Dubach Irina L, Xu Catherine K, Meisl Georg, Kosmoliaptsis Vasilis, Malinauskas Tomas, Burgess-Brown Nicola, Owens Ray, Hatch Stephanie, Mongkolsapaya Juthathip, Screaton Gavin R, Schubert Katharina, Huck John D, Liu Feimei, Pojer Florence, Lau Kelvin, Hacker David, Probst-Müller Elsbeth, Cervia Carlo, Nilsson Jakob, Boyman Onur, Saleh Lanja, Spanaus Katharina, von Eckardstein Arnold, Schaer Dominik J, Ban Nenad, Tsai Ching-Ju, Marino Jacopo, Schertler Gebhard F X, Ebert Nadine, Thiel Volker, Gottschalk Jochen, Frey Beat M, Reimann Regina R, Hornemann Simone, Ring Aaron M, Knowles Tuomas P J, Puhan Milo A, Althaus Christian L, Xenarios Ioannis, Stuart David I, Aguzzi Adriano
Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland.
Health2030 Genome Center, 9 Chemin des Mines, 1202 Geneva, Switzerland.
iScience. 2023 Feb 17;26(2):105928. doi: 10.1016/j.isci.2023.105928. Epub 2023 Jan 4.
Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.
针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）采取有效的公共卫生措施需要详细了解人群层面的免疫反应。我们开发了一种三方自动血液免疫测定法（TRABI），以评估针对三种SARS-CoV-2蛋白的IgG反应。在2019年12月至2020年12月（疫苗接种前时期），我们使用TRABI对苏黎世州的医院患者和献血者（n = 72250）进行持续血清监测。我们发现抗体以75天的半衰期衰减，而累积发病率从2020年6月的2.3%上升至2020年12月中旬的12.2%。一项后续健康调查表明，约10%感染野生型SARS-CoV-2的患者在新冠病毒病后至少十二个月仍有一些症状。至关重要的是，我们没有发现有症状感染者与无症状急性感染者在长期并发症方面存在差异的证据。无症状SARS-CoV-2感染受试者队列是研究慢性及可能意外后遗症的资源。
